Correction to: Molecular Psychiatry advance online publication, 20 December 2011; doi:10.1038/mp.2011.157
Following the online publication of this article, the authors noted the following co-authors were not included:
A Farmer6, P McGuffin6, I Craig6, C Lewis6, G Hosang6, S Cohen-Woods6, JB Vincent7, JL Kennedy7 and J Strauss7
6Institute of Psychiatry, King's College London, London, UK
7Department of Psychiatry, Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada
Also, the following Acknowledgments section was not included:
Funded by the Intramural Research Programs of the National Institute of Mental Health (NIMH) and the National Cancer Institute; Academia Sinica; and the Fondation FondaMental. Collection of samples included in this analysis was funded, in part, by the Deutsche Forschungsgemeinschaft (DFG), the National Genome Research Network (NGFN) of the Federal German Ministry of Education and Research, the Alfred Krupp von Bohlen und Halbach-Stiftung, the DFG-Graduate College 793, University of Heidelberg, the Swiss National Science Foundation (#3200B0 105993, #32003B-118308 and #33CSCO-122661) and GlaxoSmithKline (Psychiatry Center of Excellence for Drug Discovery and Genetics Division, Verona). Genotyping of the NIMH bipolar disorder samples was provided through the Genetic Association Information Network (GAIN), Foundation for NIH. Genotyping of the TGEN sample was done at the Translational Genomics Research Institute with the support of the NIMH (with thanks to David W Craig).
This research was also supported, in part, by the Intramural Research Program of the National Library of Medicine, NIH. This study utilized the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, MD.
Some of the datasets used for the analyses described in this manuscript were obtained from the database of Genotypes and Phenotypes (dbGAP phs000017.v1.p1.c1-c3). Samples and associated phenotype data were provided by the contributing studies.
This study makes use of data generated by the Wellcome Trust Case-Control Consortium. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust under award 076113 and 085475. We thank the Wellcome Trust Case Control Consortium for making data and results available for further analysis.
Data and biomaterials in the NIMH bipolar disorder sample were collected in four projects that participated in the NIMH Bipolar Disorder Genetics Initiative. From 1991 to 1998, the Principal Investigators and Co-Investigators were: Indiana University, Indianapolis, IN, U01 MH46282, John Nurnberger, MD, PhD, Marvin Miller, MD, Howard J Edenberg, PhD and Elizabeth Bowman, MD; Washington University, St Louis, MO, U01 MH46280, Theodore Reich, MD, Allison Goate, PhD, and John Rice, PhD; Johns Hopkins University, Baltimore, MD U01 MH46274, J Raymond DePaulo, Jr, MD, Sylvia Simpson, MD, MPH, and O Colin Stine, PhD; NIMH Intramural Research Program, Clinical Neurogenetics Branch, Bethesda, MD, Elliot Gershon, MD, Diane Kazuba, BA, and Elizabeth Maxwell, MSW. Data and biomaterials were also collected as part of ten projects that participated in the NIMH Bipolar.
Disorder Genetics Initiative. From 1999 to 2007, the Principal Investigators and Co-Investigators were: Indiana University, Indianapolis, IN, R01 MH59545, John Nurnberger, MD, PhD, Marvin J Miller, MD, Elizabeth S Bowman, MD, N Leela Rau, MD, P Ryan Moe, MD, Nalini Samavedy, MD, Rif El-Mallakh, MD (at University of Louisville), Husseini Manji, MD (at Wayne State University), Debra A Glitz, MD (at Wayne State University), Eric T Meyer, MS, Carrie Smiley, RN, Tatiana Foroud, PhD, Leah Flury, MS, Danielle M Dick, PhD, Howard J Edenberg, PhD; Washington University, St Louis, MO, R01 MH059534, John Rice, PhD, Theodore Reich, MD, Allison Goate, PhD, Laura Bierut, MD; Johns Hopkins University, Baltimore, MD, R01 MH59533, Melvin McInnis MD, J Raymond DePaulo, Jr, MD, Dean F MacKinnon, MD, Francis M Mondimore, MD, James B Potash, MD, Peter P Zandi, PhD, Dimitrios Avramopoulos, and Jennifer Payne; University of Pennsylvania, PA, R01 MH59553, Wade Berrettini, MD, PhD; University of California at Irvine, CA, R01 MH60068, William Byerley MD, and Mark Vawter MD; University of Iowa, IA, R01 MH059548, William Coryell MD, and Raymond Crowe MD; University of Chicago, IL, R01 MH59535, Elliot Gershon, MD, Judith Badner, PhD, Francis J McMahon, MD, Chunyu Liu, PhD, Alan Sanders, MD, Maria Caserta, MD, PhD, Steven Dinwiddie MD, Tu Nguyen, Donna Harakal; University of California at San Diego, CA, R01 MH59567, John Kelsoe, MD, Rebecca McKinney, BA; Rush University, IL, R01 MH059556, William Scheftner, MD, Howard M Kravitz, DO, MPH, Diana Marta, BS, Annette Vaughn-Brown, MSN, RN, and Laurie Bederow, MA; NIMH Intramural Research Program, Bethesda, MD, 1Z01MH002810-01, Francis J McMahon, MD, Layla Kassem, PsyD, Sevilla Detera-Wadleigh, PhD, Lisa Austin, PhD, Dennis L Murphy, MD.
The NIMH control subjects were collected by the NIMH Schizophrenia Genetics Initiative ‘Molecular Genetics of Schizophrenia II’ (MGS-II) collaboration. The Principal Investigators and Co-Investigators are: ENH/Northwestern University, Evanston, IL, MH059571, Pablo V Gejman, MD (Collaboration Coordinator; PI), Alan R Sanders, MD; Emory University School of Medicine, Atlanta, GA, MH59587, Farooq Amin, MD; Louisiana State University Health Sciences Center; New Orleans, LA, MH067257, Nancy Buccola APRN, BC, MSN; University of California-Irvine, Irvine, CA, MH60870, William Byerley, MD; Washington University, St Louis, MO, U01, MH060879, C Robert Cloninger, MD; University of Iowa, Iowa, IA, MH59566, Raymond Crowe, MD, Donald Black, MD; University of Colorado, Denver, CO, MH059565, Robert Freedman, MD; University of Pennsylvania, Philadelphia, PA, MH061675, Douglas Levinson, MD; University of Queensland, Queensland, Australia, MH059588, Bryan Mowry, MD; Mt Sinai School of Medicine, New York, NY, MH59586, Jeremy Silverman, PhD.
Cases in the German sample were collected by René Breuer, Jana Strohmaier, and Marcella Rietschel, Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Mannheim, Germany; Manuel Mattheisen, Thomas W Mühleisen, Markus M Nöthen, and Sven Cichon, Department of Genomics, Life & Brain Center, Institute of Human Genetics, and Institute of Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany; and Wolfgang Maier, Department of Psychiatry, University of Bonn, Bonn, Germany. We thank the following clinician colleagues for help in collecting the German patients: Margot Albus, Margitta Borrmann-Hassenbach, Ernst Franzek, Jürgen Fritze, Magdalena Gross, Thilo Held, Roland Kreiner, Mario Lanczik, Dirk Lichtermann, Jürgen Minges, Stephanie Ohlraun, Ulrike Reuner, Monja Tullius and Bettina Weigelt.
Cases and controls in the GSK sample were collected by Anne Farmer, Institute of Psychiatry, King's College London, UK; John B Vincent, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Canada and Richard Day and Keith Matthews at the University of Dundee, UK. We thank Peter McGuffin at the Institute of Psychiatry in London, and James L Kennedy and John Strauss at the Department of Psychiatry, University of Toronto, and Ruchi Upmanyu and Nicholas Galwey for their contributions to the GSK bipolar disorder project. We thank Federica Tozzi, Neurosciences Centre of Excellence in Drug Discovery, GlaxoSmithKline Research and Development, Verona, Italy.
The FondaMental sample was collected by Stéphane Jamain, Bruno Etain, Chantal Henry, Frank Bellivier and Marion Leboyer, Inserm U955, Psychiatrie Génétique, Créteil, France, as well as Jean-Pierre Kahn CHU de Nancy, Toul, France. We thank the Centre National de Génotypage for genotyping, the banque de cellules de l’hôpital Cochin (J Chelly) and the Plateforme de Ressources Biologique Groupe Hopsitalier A Chenevier—H Mondor (B Ghaleh) for DNA collections. The recruitment of patients was supported by ANR (ANR NEURO2006, MANAGE_BPAD), INSERM, AP-HP, and the Fondation FondaMental (http://www.fondation-fondamental.org).
This project was approved by the CNS Institutional Review Board at the National Institutes of Health and by the GAIN Data Access Committee. Informed consent was obtained from all subjects.
Additional acknowledgements are included at http://mapgenetics.nimh.nih.gov.
About this article
Genetic validation of bipolar disorder identified by automated phenotyping using electronic health records
Translational Psychiatry (2018)